Shutting the gate: targeting endocytosis in acute leukemia

Cedric S Tremblay; Stephen B Ting; Adam McCluskey; Phillip J Robinson; David J Curtis

doi:10.1016/j.exphem.2021.09.003

Shutting the gate: targeting endocytosis in acute leukemia

Exp Hematol. 2021 Dec:104:17-31. doi: 10.1016/j.exphem.2021.09.003. Epub 2021 Sep 23.

Authors

Cedric S Tremblay¹, Stephen B Ting², Adam McCluskey³, Phillip J Robinson⁴, David J Curtis⁵

Affiliations

¹ Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia. Electronic address: cedric.tremblay@monash.edu.
² Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Eastern Health, Box Hill, Victoria, Australia; Department of Clinical Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
³ Chemistry, Centre for Chemical Biology, School of Environmental and Life Sciences, University of Newcastle, Callaghan, New South Wales, Australia.
⁴ Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia; Cell Signalling Unit, Children's Medical Research Institute, Sydney, New South Wales, Australia.
⁵ Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Alfred Hospital, Melbourne, Victoria, Australia.

PMID: 34563604
DOI: 10.1016/j.exphem.2021.09.003

Abstract

Endocytosis entails selective packaging of cell surface cargos in cytoplasmic vesicles, thereby controlling key intrinsic cellular processes as well as the response of normal and malignant cells to their microenvironment. The purpose of this review is to outline the latest advances in the development of endocytosis-targeting therapeutic strategies in hematological malignancies.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Endocytosis / drug effects*
Hematologic Neoplasms / drug therapy
Hematologic Neoplasms / pathology
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / pathology
Molecular Targeted Therapy* / methods
Tumor Microenvironment / drug effects

Substances

Antineoplastic Agents